Pacira BioSciences (NASDAQ:PCRX) Price Target Raised to $30.00

Pacira BioSciences (NASDAQ:PCRX) had its price objective boosted by Needham & Company LLC from $22.00 to $30.00 in a report published on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other brokerages have also recently commented on PCRX. Barclays decreased their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 12th. Royal Bank of Canada lifted their price target on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 7th. HC Wainwright restated a “buy” rating and issued a $39.00 price objective on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Finally, Jefferies Financial Group lifted their target price on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Pacira BioSciences has an average rating of “Hold” and a consensus target price of $24.50.

Pacira BioSciences Trading Up 6.5 %

PCRX stock opened at $21.88 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The business has a fifty day moving average of $18.52 and a two-hundred day moving average of $17.52. Pacira BioSciences has a 52-week low of $11.16 and a 52-week high of $34.01.

Hedge Funds Weigh In On Pacira BioSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. boosted its stake in Pacira BioSciences by 129.4% during the third quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock worth $74,681,000 after buying an additional 2,799,434 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Pacira BioSciences by 9.8% in the second quarter. Renaissance Technologies LLC now owns 2,066,197 shares of the company’s stock valued at $59,114,000 after buying an additional 184,000 shares during the last quarter. State Street Corp raised its holdings in shares of Pacira BioSciences by 5.8% in the third quarter. State Street Corp now owns 2,014,012 shares of the company’s stock valued at $30,311,000 after buying an additional 110,162 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Pacira BioSciences by 12.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock worth $52,300,000 after purchasing an additional 198,936 shares during the last quarter. Finally, Doma Perpetual Capital Management LLC raised its holdings in Pacira BioSciences by 71.8% during the 2nd quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company’s stock worth $28,632,000 after purchasing an additional 418,321 shares during the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.